MRC1 and Lynch syndrome: Recent adjustments to the NCCN genetic testing criteria for Lynch syndrome (version 3.2017) now include an indication for ovarian cancer patients with a 5% or greater likelihood of detecting a pathogenic variant in a MMR gene calculated by certain prediction models.